Upcoming event

Tags

3D reconstruction, Article of the Month, Artificial intelligence, ASCO GU22, ASCO21, AUA21, augmented reality, biomarkers, Cabozantinib, Carcinoma, CheckMate-214, CheckMate-9ER, Checkpoint Inhibitor, Chronic kidney disease, clampless surgery, Cryosurgery, cystic masses, EAU, EAU21, EAU22, EMUC21, EMUC22, enucleoresection, ERUS 2026, ERUS22, ESMO21, ESMO25, expert interview, Frail patient​, Glomerular filtration rate, Guidelines, histology, imaging, IMDC risk model, International Metastatic Renal Cell Carcinoma Database Consortium, intraoperative cyst rupture, intraoperative ultrasound, Kidney cancer, Laparoscopy, localised renal cell carcinoma, Lymph node metastases, Lymph nodes, Metastasectomy, metastatic disease, metastatic RCC, Mortality, neoadjuvant immunotherapy, Neoplasm metastasis, Neoplasm recurrence, Nephrectomy, Nephron-sparing surgery, Nivolumab, Overall survival, papillary tumour, Partial nephrectomy, precision therapy, Prognostication, Radical nephrectomy, Radical surgery, RCC, Renal cancer, Renal cell, Renal cell carcinoma, Renal Cell Carcinoma guidelines, Renal cryoablation, Renal function, Renal Transplantation, Renorrhaphy, risk stratification, robot-assisted partial nephrectomy, Robotic, robotic partial nephrectomy, Robotic prostatectomy, Robotic surgery, selective clamping, stereotactic body radiation therapy, Survival outcome, Suture, sutureless partial nephrectomy, Targeted therapies, Treatment response, tumour enucleation, tumour genomics, tumour pseudocapsule rupture, Urological surgery, UROonco2025, UROonco24, UROonco25, UROwebinar, Webinar, zero-ischaemia surgery
Show all

Phase 1b/2 study of combination 177Lu girentuximab plus cabozantinib and nivolumab in treatment naive patients with advanced clear cell RCC

Stereotactic body radiotherapy for primary renal cell carcinoma: a systematic review and practice guideline from the International Society of Stereotactic Radiosurgery (ISRS)

The Lancet Oncology, January 2024

Nephron Sparing Treatment (NEST) for small renal masses: A feasibility cohort-embedded randomised controlled trial comparing percutaneous cryoablation and robot-assisted partial nephrectomy

Development of a novel score (RENSAFE) to determine probability of acute kidney injury and renal functional decline post surgery: A multicenter analysis

Preoperative renal parenchyma volume as a predictor of kidney function following nephrectomy of complex renal masses

Phase II LITESPARK-003 study of belzutifan in combination with cabozantinib for advanced clear cell renal cell carcinoma

ESMO Congress 2023

Belzutifan versus everolimus in participants with previously treated advanced clear cell renal cell carcinoma: Randomized open-label phase III LITESPARK-005 study

Safety and efficacy of two doses of belzutifan in patients with advanced RCC: Results of the randomized phase II LITESPARK-013 study

Patient-reported outcome measurement and reporting for patients with advanced renal cell carcinoma: A systematic literature review

Multimodal recurrence scoring system for prediction of clear cell renal cell carcinoma outcome: a discovery and validation study

Cabozantinib plus Nivolumab and Ipilimumab in Renal-Cell Carcinoma

Risks and benefits of partial nephrectomy performed with limited or with zero ischaemia time

PreviousNext